ATE278957T1 - Verfahren zur unterstützung der diagnose der alzheimerschen krankheit durch messung der amyloid-beta-peptide(x groesser als oder gleich 41) und tau - Google Patents

Verfahren zur unterstützung der diagnose der alzheimerschen krankheit durch messung der amyloid-beta-peptide(x groesser als oder gleich 41) und tau

Info

Publication number
ATE278957T1
ATE278957T1 AT95939892T AT95939892T ATE278957T1 AT E278957 T1 ATE278957 T1 AT E278957T1 AT 95939892 T AT95939892 T AT 95939892T AT 95939892 T AT95939892 T AT 95939892T AT E278957 T1 ATE278957 T1 AT E278957T1
Authority
AT
Austria
Prior art keywords
alzheimer
diagnosis
disease
tau
aiding
Prior art date
Application number
AT95939892T
Other languages
English (en)
Inventor
Peter A Seubert
Carmen Vigo-Pelfrey
Dale B Schenk
Robin Barbour
Original Assignee
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26991508&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE278957(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/339,141 external-priority patent/US6114133A/en
Application filed by Elan Pharm Inc filed Critical Elan Pharm Inc
Application granted granted Critical
Publication of ATE278957T1 publication Critical patent/ATE278957T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT95939892T 1994-11-14 1995-11-13 Verfahren zur unterstützung der diagnose der alzheimerschen krankheit durch messung der amyloid-beta-peptide(x groesser als oder gleich 41) und tau ATE278957T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/339,141 US6114133A (en) 1994-11-14 1994-11-14 Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
US41900895A 1995-04-07 1995-04-07
PCT/US1995/014659 WO1996015452A1 (en) 1994-11-14 1995-11-13 METHODS FOR AIDING IN THE DIAGNOSIS OF ALZHEIMER'S DISEASE BY MEASURING AMYLOID-β PEPTIDE (X- ≥41) AND TAU

Publications (1)

Publication Number Publication Date
ATE278957T1 true ATE278957T1 (de) 2004-10-15

Family

ID=26991508

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95939892T ATE278957T1 (de) 1994-11-14 1995-11-13 Verfahren zur unterstützung der diagnose der alzheimerschen krankheit durch messung der amyloid-beta-peptide(x groesser als oder gleich 41) und tau

Country Status (11)

Country Link
US (4) US7427392B1 (de)
EP (2) EP0792458B1 (de)
JP (2) JP3634375B2 (de)
AT (1) ATE278957T1 (de)
AU (1) AU705907B2 (de)
CA (1) CA2205359C (de)
DE (1) DE69533623T2 (de)
DK (1) DK0792458T3 (de)
ES (1) ES2230551T3 (de)
PT (1) PT792458E (de)
WO (1) WO1996015452A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610493B1 (en) 1993-06-17 2003-08-26 Brigham And Women's Hospital Screening compounds for the ability to alter the production of amyloid-β peptide
US7427392B1 (en) 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
BR9913112A (pt) * 1998-09-08 2001-05-08 Innogenetics Nv Tau como um marcador para dano inicial de cns
CA2414772C (en) 2000-07-07 2011-06-28 Jan Naslund Prevention and treatment of alzheimer's disease
US20070128191A1 (en) * 2001-12-26 2007-06-07 Universidad De Zaragoza Polyclonal antibodies, preparation method thereof and use of same
US8360992B2 (en) 2002-04-19 2013-01-29 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
ES2246178B1 (es) * 2003-05-08 2007-03-01 Universidad De Zaragoza. Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
US20090123952A1 (en) * 2004-11-12 2009-05-14 Pfizer, Inc. Method of Measuring Amyloid-Beta Peptides
WO2007044094A1 (en) * 2005-10-11 2007-04-19 Blanchette Rockefeller Neurosciences Institute Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio as alzheimer's disease-specific molecular biomarkers (adsmb)
RU2429244C2 (ru) 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
TW200844110A (en) 2007-01-11 2008-11-16 Univ Marburg Philipps Diagnosis and treatment of alzheimer's disease and other neurodementing diseases
EP1944314A1 (de) * 2007-01-11 2008-07-16 Philipps-Universität Marburg Diagnose von Morbus Alzheimer und anderen Demenzerkrankungen
EP2145014B1 (de) * 2007-04-05 2012-12-12 The J. David Gladstone Institutes Neuronale überanregung reduzierende agentien
EP2009445A1 (de) * 2007-06-29 2008-12-31 Institut Pasteur Verwendung von Einzeldomänen-Camelid-Antikörpern zur Entdeckung einer oligomeren Form eines Amyloid-Betapeptids und deren Anwendungen
EP2020602A1 (de) * 2007-08-02 2009-02-04 Araclon Biotech Hochempfindliche Immuntests und Kits zur Bestimmung biologisch interessanter Peptide und Proteine
WO2010099199A1 (en) * 2009-02-24 2010-09-02 Gibbons Winton G Detection of complexes of tau and amyloid
HUE055739T2 (hu) * 2009-03-18 2021-12-28 Ac Immune Sa Eljárás terápiás alkalmazásra
UA107571C2 (xx) * 2009-04-03 2015-01-26 Фармацевтична композиція
EP2258398A1 (de) 2009-05-26 2010-12-08 Araclón Biotech, S. L. Albumin/Amyloidpeptid-Konjugate und deren Verwendungen
WO2012142301A2 (en) 2011-04-12 2012-10-18 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patients recovery from a brain injury
PT2579042E (pt) * 2011-10-04 2014-09-09 Affiris Ag Método para detecção de anticorpos específicos para a numa amostra biológica.
DE102011057021A1 (de) * 2011-12-23 2013-06-27 Forschungszentrum Jülich GmbH Verfahren zur selektiven Quantifizierung von A-Beta-Aggregaten
EP2808679A4 (de) 2012-01-27 2015-01-14 Panasonic Healthcare Co Ltd Diagnoseverfahren und diagnosesystem für morbus alzheimer
RU2644242C2 (ru) 2012-04-05 2018-02-08 Ац Иммуне С.А. Гуманизированное тау-антитело
NZ630542A (en) 2012-08-16 2017-06-30 Ipierian Inc Methods of treating a tauopathy
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
ES2495266B8 (es) 2013-02-13 2015-11-12 Consejo Superior De Investigaciones Científicas (Csic) Uso de igf-1 como reactivo de diagnóstico y/o pronóstico precoz de la enfermedad de alzheimer
US10501531B2 (en) 2013-03-13 2019-12-10 Prothena Biosciences Limited Tau immunotherapy
WO2014150877A2 (en) 2013-03-15 2014-09-25 Ac Immune S.A. Anti-tau antibodies and methods of use
KR20140128230A (ko) * 2013-04-26 2014-11-05 한국과학기술연구원 혈액 중 단백질 응집체의 용해를 통한 단백질의 비정상적인 응집 또는 미스폴딩과 관련된 질환 또는 질병을 진단하는 진단키트
WO2015020523A1 (en) 2013-08-07 2015-02-12 Stichting Vu-Vumc Biomarkers for early diagnosis of alzheimer's disease
JP2017512751A (ja) 2014-02-14 2017-05-25 アイピエリアン，インコーポレイティド タウペプチド、抗タウ抗体、およびそれらの使用方法
KR101890978B1 (ko) 2014-06-17 2018-08-24 서울대학교산학협력단 알츠하이머 질환 모델용 형질전환 돼지 및 이의 용도
WO2016005466A2 (en) 2014-07-10 2016-01-14 Bioarctic Neuroscience Ab IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES
PT3452507T (pt) 2016-05-02 2022-12-20 Prothena Biosciences Ltd Imunoterapia anti-tau
MX2018013386A (es) * 2016-05-02 2019-02-28 Prothena Biosciences Ltd Anticuerpos que reconocen tau.
MY198194A (en) 2016-05-02 2023-08-09 Prothena Biosciences Ltd Antibodies Recognizing Tau
KR102784294B1 (ko) 2017-05-02 2025-03-19 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
CN111787942B (zh) 2017-10-25 2024-03-29 杨森制药公司 磷酸化Tau肽的组合物及其用途
US20220000428A1 (en) 2018-11-14 2022-01-06 Qynapse Method for determining a prediction model, method for predicting the evolution of a k-uplet of mk markers and associated device
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
MY206596A (en) 2019-02-08 2024-12-25 Janssen Pharmaceuticals Inc Method of safe administration of phosphorylated tau peptide vaccine
JP7630834B2 (ja) 2019-03-03 2025-02-18 プロセナ バイオサイエンシーズ リミテッド タウ認識抗体
JOP20210284A1 (ar) 2019-04-24 2023-01-30 Janssen Pharmaceuticals Inc الإعطاء غير المتجانس للقاحات تاو
EP4157338A4 (de) 2020-05-26 2024-11-13 TrueBinding, Inc. Verfahren zur behandlung von entzündungskrankheiten durch galectin-3-blockierung

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4271140A (en) 1978-01-23 1981-06-02 Baxter Travenol Laboratories, Inc. Method and composition for double receptor, specific binding assays
US4474892A (en) 1983-02-16 1984-10-02 Board Of Trustees Of The Leland Stanford Junior University Two-site immunoassays using monoclonal antibodies of different classes or subclasses and test kits for performing same
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
JPS6267297A (ja) 1985-09-18 1987-03-26 Hitachi Ltd ポンプの軸受潤滑装置
US5223482A (en) * 1986-11-17 1993-06-29 Scios Nova Inc. Recombinant Alzheimer's protease inhibitory amyloid protein and method of use
US5220013A (en) * 1986-11-17 1993-06-15 Scios Nova Inc. DNA sequence useful for the detection of Alzheimer's disease
EP0332640A1 (de) 1986-11-17 1989-09-20 California Biotechnology, Inc. Rekombinantes alzheimer-amyloidprotein
US5547841A (en) * 1987-10-08 1996-08-20 The Mclean Hospital Corporation In vitro method for screening for drugs that inhibit production or degradation of human A4-amyloid
US5262332A (en) * 1989-04-05 1993-11-16 Brigham And Women's Hospital Diagnostic method for Alzheimer's disease: examination of non-neural tissue
WO1990012871A1 (en) 1989-04-14 1990-11-01 Research Foundation For Mental Hygiene, Inc. Cerebrovascular amyloid protein-specific monoclonal antibody sv17-6e10
AU5525090A (en) 1989-04-14 1990-11-16 Research Foundation For Mental Hygiene, Inc. Monoclonal antibody to amyloid peptide
US5234814A (en) * 1989-06-01 1993-08-10 Du Pont Merck Pharmaceutical Company Diagnostic assay for alzheimer's disease
AU7121191A (en) 1990-02-26 1991-10-10 Albert Einstein College Of Medicine Of Yeshiva University Diagnostic assay for alzheimer's disease
US5213962A (en) * 1990-04-24 1993-05-25 The Regents Of The University Of California Purification, detection and methods of use of protease Nexin-2
ES2217250T3 (es) * 1990-06-15 2004-11-01 Scios Inc. Mamifero transgenico, no humano que muestra la patologia de formacion amiloides de la enfermedad de alzheimer.
JPH04252955A (ja) 1991-01-29 1992-09-08 Asahi Chem Ind Co Ltd 蛋白質の測定方法、試薬及びキット
JPH04252956A (ja) 1991-01-29 1992-09-08 Asahi Chem Ind Co Ltd タンパク質の測定方法、試薬及びキット
JPH04252954A (ja) 1991-01-29 1992-09-08 Asahi Chem Ind Co Ltd タンパクの測定方法、試薬及びキット
AU671093B2 (en) 1992-01-07 1996-08-15 Elan Pharmaceuticals, Inc. Transgenic animal models for alzheimer's disease
US5604102A (en) * 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
US5766846A (en) 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US5837672A (en) 1992-07-10 1998-11-17 Athena Neurosciences, Inc. Methods and compositions for the detection of soluble β-amyloid peptide
US6610493B1 (en) 1993-06-17 2003-08-26 Brigham And Women's Hospital Screening compounds for the ability to alter the production of amyloid-β peptide
DE69334337D1 (de) 1992-10-26 2010-08-26 Elan Pharm Inc Verfahren zur Identifizierung von Hemmstoffverbindungen der Freisetzung von Beta-Amyloidpeptid (BAP)
ATE239797T1 (de) 1993-01-25 2003-05-15 Takeda Chemical Industries Ltd Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
US6114133A (en) 1994-11-14 2000-09-05 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
US7427392B1 (en) 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
US5786180A (en) 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
JP5025871B2 (ja) 2000-02-21 2012-09-12 エイチ．リュンドベック エイ／エス アミロイドの新規なダウン−レギュレート方法
WO2003051374A2 (en) * 2001-12-17 2003-06-26 New York State Office Of Mental Health SEQUESTRATION OF Aβ IN THE PERIPHERY IN THE ABSENCE OF IMMUNOMODULATING AGENT AS A THERAPEUTIC APPROACH FOR THE TREATMENT OR PREVENTION OF BETA-AMYLOID RELATED DISEASES
JP4252955B2 (ja) 2002-07-01 2009-04-08 ソニー エリクソン モバイル コミュニケーションズ， エービー 電子通信装置に対してテキストを入力する方法
AU2003275708A1 (en) 2002-10-29 2004-05-25 Hoya Corporation Chemically strengthened glass, substrate for information recording medium and information recording medium
JP4252954B2 (ja) 2004-12-02 2009-04-08 インターナショナル・ビジネス・マシーンズ・コーポレーション 情報処理装置、情報処理装置のパワーマネージメント方法、およびそのためのプログラム

Also Published As

Publication number Publication date
US20050069968A1 (en) 2005-03-31
EP0792458A4 (de) 1999-04-07
US7700309B2 (en) 2010-04-20
JP3634375B2 (ja) 2005-03-30
US20040253643A1 (en) 2004-12-16
CA2205359C (en) 2006-07-04
US7427392B1 (en) 2008-09-23
CA2205359A1 (en) 1996-05-23
EP1491889A2 (de) 2004-12-29
DK0792458T3 (da) 2005-01-31
DE69533623T2 (de) 2006-03-02
JP2004077499A (ja) 2004-03-11
EP1491889A3 (de) 2005-04-06
AU4154496A (en) 1996-06-06
US20040265920A1 (en) 2004-12-30
EP0792458B1 (de) 2004-10-06
DE69533623D1 (de) 2004-11-11
WO1996015452A1 (en) 1996-05-23
US7811769B2 (en) 2010-10-12
JPH10509797A (ja) 1998-09-22
ES2230551T3 (es) 2005-05-01
EP0792458A1 (de) 1997-09-03
AU705907B2 (en) 1999-06-03
PT792458E (pt) 2005-02-28

Similar Documents

Publication Publication Date Title
ATE278957T1 (de) Verfahren zur unterstützung der diagnose der alzheimerschen krankheit durch messung der amyloid-beta-peptide(x groesser als oder gleich 41) und tau
DE69707266D1 (de) Verfahren zum überwachen der gesundheit eines patienten durch messen und vorhersage des glucosespiegels einer blutprobe des patienten
DE10345171A1 (de) Überwachungssystem für Patienten
ATE160875T1 (de) Verfahren zum nachweis und/oder zur bestimmung und/oder zur isolierung von apoptotischen zellen in oder aus einer probe
ATE202849T1 (de) Verwendung von humanem neutrophil-lipocalin(hnl) als diagnostischer marker und anti-hnl- antikörperzubereitung
ATE23067T1 (de) Verfahren und vorrichtung zur selbstueberpruefung von mikrorechnergesteuerten schaltgeraeten, insbesondere in kraftfahrzeugen.
Boston Initial in vitro evaluation of DIAGNOdent for detecting secondary carious lesions associated with resin composite restorations.
EP1226783A3 (de) Verfahren und medizinisches System zur Überwachung eines an Epilepsie leidenden Patienten
DE69221666D1 (de) Verfahren zur Diagnose von Nierenkrankheiten durch Nachweisung von Albuminfragmenten
DE69121990D1 (de) Verfahren zur immunologischen Bestimmung des carboxyterminalen Peptids von Typ-I-Prokollagen
Price et al. Allergy to rabbits: II. Identification and characterization of a major rabbit allergen
JPH02243951A (ja) 鉄筋コンクリート内部の鋼材の腐食を診断するための方法
Hinrichs et al. A comparison of 3 systems for quantifying gingival crevicular fluid with respect to linearity and the effects of qualitative differences in fluids
JPH04109142A (ja) 加硫ゴムのオゾン劣化試験方法
DE60043146D1 (de) Immuntest für humanes Medullasin und Verfahren zur Diagnose von multipler Sklerose
Mutti et al. Reference values for early markers of renal damage
JP4735503B2 (ja) 腹膜機能マーカー、その分析方法およびその用途
EP0621480A3 (de) Diagnose und Überwachung von Patienten mit Lungenkrebs durch Messung von NCA 50/90 im Blut.
EP0628820A3 (de) Diagnose und Überwachung von Patienten mit Dickdarmkrebs durch Messung von NCA 50/90 im Blut.
Meier-Ruge Morphometric methods and their potential value for gerontological brain research
RU1796143C (ru) Устройство дл определени времени восстановлени парциального давлени кислорода в ткани в постишимическом периоде
JPS62103591A (ja) 体表面モニタ
Hassan et al. Diagnosis of dental erosion using intraoral scanner in comparison to 3D confocal laser microscope
RU2159576C2 (ru) Способ оценки величины воздействия на организм человека различных нагрузок
JPH04204056A (ja) ストレス検査方法および装置

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0792458

Country of ref document: EP